Figure 3From: Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention Effect on study power when follow-up for primary endpoint increased from 40 to 52 weeks for different assumptions concerning adherence and HIV incidence.Back to article page